Health and intellectual property rights
The UK Competition Appeal Tribunal’s Misguided Reprieve for Pfizer’s Excessive Pricing Abuse
Excessive Pricing and Sham Patent Litigation: The Pfizer and AbbVie Decisions
US Section 301, China, and technology transfer: Law and its limitations revisited (again)
Book Review: Intellectual Property Rights and Climate Change
Let International Competition Negotiations Sleep a While Longer: Focus on Tools and Capacity
Comment on the US Supreme Court Decision “Impression Products v. Lexmark International”, 35 U.S.C., §154(a)
The Evolution of Public Health Provisions in Preferential Trade and Investment Agreements of the United States
